

17

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 29554/01 Confirmation No. :
First Named Inventor : Marc G. ACHEN
Filed : January 18, 2001
TC/A.U. : (To Be Assigned)
Examiner : (To Be Assigned)
Docket No. : 029065.48505AU
Customer No. : 23911
Title : Vegf-D/ Vegf-C/vegf Peptidomimetic Inhibitors

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R §§ 1.97 AND 1.98**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This supplements the Information Disclosure Statement submitted in the above-identified application on July 27, 2001.

Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached Form PTO-1449 listed herein and which the Examiner may deem relevant to patentability of the claims of the above-identified application.

Applicant encloses herewith a copy of a corresponding European Search Report citing such documents, together with an English-language version (if not already included) of that portion of the Search Report indicating the degree of relevance found by the foreign office.

The present Information Disclosure Statement is being filed after the later of three months from the application's filing date and the mailing date of the first Office Action on the merits, but before a Final Office Action or Notice of Allowance (whichever is earlier), and therefore Applicant is filing concurrently

herewith a Statement under 37 C.F.R. § 1.97(e). No fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

If necessary, the paper should be considered as a petition for consideration of the Information Disclosure Statement under 37 C.F.R. § 1.97(d)(1) and that the petition fee set forth in 37 C.F.R. § 1.17(p) in accordance with 37 C.F.R. § 1.97(d)(2) should be charged to Deposit Account 05-1323, Attorney Docket No.: 029065.48505AU.

July 5, 2005


Respectfully submitted,



J. D. Evans
Registration No. 26,269

Kening Li, Ph.D.
Registration No. 44,872

CROWELL & MORING LLP
Intellectual Property Group
P.O. Box 14300
Washington, DC 20044-4300
Telephone No.: (202) 624-2500
Facsimile No.: (202) 628-8844
JDE:KLI:lck



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known			
		Application Number	09/761,636		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	January 18, 2001		
		First Named Inventor	Marc G. ACHEN		
		Art Unit	1644		
		Examiner Name	P. N. HUYNH		
Sheet	1	of	1	Attorney Docket Number	1064/48505

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

FOREIGN PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)					
	AA	WO 99/40947		08-19-1999	Resolution Pharmaceuticals Inc.		
	AB	EP 0467701		01-22-1992	Merck & Co., Inc.		
	AC	WO 95/34312		12-21-1995	The Trustees of the University of Pennsylvania		
	AD	WO 98/07832		02-26-1998	Ludwig Institute for Cancer Research		
	AE	WO 99/66954		12-29-1999	United Biomedical Inc.		
	AF	WO 00/75176		12-14-2000	The University of Melbourne		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.